BCRX

#1599
BioCryst Pharmaceuticals, Inc. - Common Stock
8.9 1 USD
-1.87%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
8.91
8.91
Range Annuel
6.00
11.31
Changement quotidien
-1.87%
Changement Mensuel
-1.11%
Evolution sur 6 mois
+25.85%
Changement Annuel
-17.88%
Clôture Précédente
9.0 8
Open
8.9 1
Low
8.9 1
High
8.9 1
Volume
277
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
  • Market Capitalization 2.26 B
  • Employee 435
  • Founded 1986
  • CEO Jon P. Stonehouse
  • Website www.biocryst.com
  • Headquarter Delaware, United States
  • FIGI BBG000BLYWX6
  • Industry Biotechnologies
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
6.45
ratio cours/chiffre d'affaires
1.95

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

Nouvelles